Engineers Gate Manager’s 4D Molecular Therapeutics FDMT Stock Holding History

Engineers Gate Manager’s Portfolio FDMT Stock Details FDMT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$907K	Buy	68,206 +38,806	+132%	+$378K	0.01%	1148
2026 Q1	$274K	Sell	29,400 -44,869	-60%	-$390K	﹤0.01%	1750
2025 Q4	$557K	Buy	+74,269	New	+$753K	0.01%	1306
2025 Q3	–	Sell	-24,015	Closed	-$89.1K	–	2279
2025 Q2	$89.1K	Sell	24,015 -49,407	-67%	-$174K	﹤0.01%	2007
2025 Q1	$237K	Sell	73,422 -98,000	-57%	-$462K	﹤0.01%	1814
2024 Q4	$955K	Buy	171,422 +111,817	+188%	+$877K	0.02%	1041
2024 Q3	$644K	Sell	59,605 -3,444	-5%	-$57.2K	0.01%	1260
2024 Q2	$1.32M	Buy	63,049 +45,884	+267%	+$1.15M	0.03%	756
2024 Q1	$547K	Buy	+17,165	New	+$438K	0.01%	1154
2021 Q1	–	Sell	-8,139	Closed	-$337K	–	1901
2020 Q4	$337K	Buy	+8,139	New	+$336K	0.01%	1220

Other funds holding FDMT

Jupiter Topco New York $245B AUM

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

NHAS

Novo Holdings A/S Hellerup, Denmark $1.72B AUM 106.92% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

TECP

Trails Edge Capital Partners Atlanta, Georgia $630M AUM

Engineers Gate Manager's FDMT Position: Q2 2026 in Review

Engineers Gate Manager increased its 4D Molecular Therapeutics (FDMT) stake by 132% in Q2 2026, buying an estimated $378K and bringing the position to 68,206 shares worth $907K. The position accounts for 0.01% of the portfolio, ranked #1148.

Engineers Gate Manager first reported a position in FDMT in Q4 2020 and has held it in 10 quarters since. The position peaked at $1.32M in Q2 2024. 158 funds tracked by Wall St. Rank hold FDMT as of Q2 2026.

Engineers Gate Manager held 68,206 shares of 4D Molecular Therapeutics worth $907K as of Q2 2026.
Engineers Gate Manager bought 38,806 4D Molecular Therapeutics shares in Q2 2026, an estimated $378K.
4D Molecular Therapeutics made up 0.01% of Engineers Gate Manager's portfolio in Q2 2026, its #1148 holding.
Engineers Gate Manager first reported a position in 4D Molecular Therapeutics in Q4 2020 and has held it in 10 quarters since.
Engineers Gate Manager's 4D Molecular Therapeutics position peaked at $1.32M in Q2 2024.
158 funds tracked by Wall St. Rank held 4D Molecular Therapeutics as of Q2 2026.

Based on Engineers Gate Manager's 13F filing for Q2 2026, filed 14 Aug 2026.